What's in Immunovant Sciences GmbH's pipeline?

Immunovant Sciences GmbH has 3 drugs in our index: 0 marketed, 0 filed, 2 in Phase 3, 1 in Phase 2, 0 in Phase 1.

Which companies overlap with Immunovant Sciences GmbH's portfolio?

Top competitors by shared drug class: Amgen, argenx.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/immunovant-sciences-gmbh.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

Immunovant Sciences GmbH — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Immunovant Sciences GmbH pipeline: 0 marketed, 0 filed, 2 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
IMVT-1402	IMVT-1402	phase 3	FcRn antagonist	FcRn (neonatal Fc receptor)	Immunology
Matching Placebo SC	Matching Placebo SC	phase 3

Therapeutic area mix

Immunology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Amgen · 1 shared drug class
argenx · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Immunovant Sciences GmbH:

Cite this brief

Drug Landscape (2026). Immunovant Sciences GmbH — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/immunovant-sciences-gmbh. Accessed 2026-06-10.